ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 2886

Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries

Emily Somers1, Lu Wang 2, W Joseph McCune 3, S Sam Lim 4, Cristina Drenkard 4, Elizabeth Ferucci 5, Maria Dall'Era 6, Caroline Gordon 7, Charles Helmick 8, Hilary Parton 9 and Peter Izmirly 10, 1University of Michigan Schools of Medicine & Public Health, Ann Arbor, MI, 2University of Michigan, Ann Arbor, 3University of Michigan, Ann Arbor, MI, 4Emory University, Atlanta, GA, 5Alaska Native Tribal Health Consortium, Anchorage, AK, 6University of California, San Francisco, San Francisco, CA, 7University of Birmingham, Birmingham, United Kingdom, 8Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, 9New York City Department of Health & Mental Hygiene, Long Island City, NY, 10NYU School of Medicine, New York

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: epidemiologic methods and meta-analysis, Lupus

Session Information

Date: Wednesday, November 13, 2019

Title: 6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)

Session Type: ACR Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: The heterogeneity of the clinical manifestations of systemic lupus erythematosus (SLE) and lack of a diagnostic test make SLE difficult for epidemiologists to study. The Centers for Disease Control and Prevention (CDC) supported five population-based SLE surveillance registries, using harmonized methodology, to better estimate incidence and prevalence of SLE in diverse areas in the United States (US). Leveraging these data, we performed a meta-analysis to estimate the general prevalence of SLE in the US.

Methods: The CDC registries were established in Michigan, Georgia, California, New York and the through the Indian Health Service (IHS).  All registries used the 1997 revised ACR classification criteria for SLE as their primary case definition, and the surveillance time periods ranged from 2003 to 2009. Age-standardized prevalence was stratified by sex and race/ethnicity from the state-based registries; the American Indian/Alaska Native (AI/AN) estimate was based on the IHS registry that covered multiple states.  For pooling data across the four sites with data on different racial/ethnic groups, we used Cochran’s Q and I² statistic to test for heterogeneity across sites. Due to significant heterogeneity, we used a random effects model to calculate pooled prevalence, which allows for more variation across sites.   We then extrapolated to the 2017 Census population data according to sex and race-stratified groups, including data from the IHS registry, and summed the stratum-specific estimates to provide a total population estimate of SLE cases in the US.

Results: The registries contributed 5,417 classified cases of SLE from a mix of urban and rural areas. From the meta-analysis of the four state-based registries, the overall prevalence was 72.8 (95%CI 65.3, 81.0) per 100,000 population. The prevalence among females was about 9 times higher than males (128.7 vs 14.6). In the meta-analysis, prevalence was highest among black females (230.9, 95%CI 178.2, 299.2), followed by Hispanic females (120.7, 95%CI 84.0, 173.4), white females (84.7, 95%CI 68.4, 104.8) and Asian/Pacific Islander females (84.4, 95%CI 48.3, 147.4). Among males, prevalence followed a similar pattern with the highest rates among black males (26.7, 95%CI 19.6, 36.4) followed by Hispanic males (18.0, 95%CI 15.6, 20.8), Asian/Pacific Islander males (11.2, 95%CI 5.7, 21.9), and white males (8.9, 95%CI 8.0, 10.1). The AI/AN prevalence estimates, which were not included in the meta-analysis, had the highest rates of SLE for both females (271, 95%CI 238, 307) and males (54, 95%CI 36, 77). Applying our sex- and race-specific prevalence estimates to the corresponding population denominators from 2017 Census data, we estimated that 198,677 persons (179,186 females and 19,491 males) in the US fulfill ACR SLE classification criteria, Table 1.

Conclusion: Using estimates from a coordinated network of population-based SLE registries, a more accurate prevalence estimate for the US was obtained. Our methods did not capture undiagnosed, “incomplete”, or other forms of lupus such as cutaneous lupus. Other case definitions may yield different results.


TableAbsv4caption


Disclosure: E. Somers, None; L. Wang, None; W. McCune, None; S. Lim, None; C. Drenkard, None; E. Ferucci, None; M. Dall'Era, Biogen,, 5, Genentech, 5, Janssen Pharmaceuticals, 5, Kezar Life Sciences, 2, Pfizer, 5; C. Gordon, Bristol-Myers Squibb, 5, 8, Centers for Disease Control and Prevention, 5, Eli Lilly, 5, 8, EMD Serono, 5, EMD Serono, UCB, 5, GlaxoSmithKline, 5, 8, Merck Serono, 5, 8, UCB, 2, 5, 8, Versus Arthritis/GSK, 2; C. Helmick, None; H. Parton, None; P. Izmirly, GlaxoSmithKline, 5.

To cite this abstract in AMA style:

Somers E, Wang L, McCune W, Lim S, Drenkard C, Ferucci E, Dall'Era M, Gordon C, Helmick C, Parton H, Izmirly P. Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-systemic-lupus-erythematosus-in-the-united-states-preliminary-estimates-from-a-meta-analysis-of-the-centers-for-disease-control-and-prevention-lupus-registries/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-systemic-lupus-erythematosus-in-the-united-states-preliminary-estimates-from-a-meta-analysis-of-the-centers-for-disease-control-and-prevention-lupus-registries/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology